Results Generated From:
EMBASE <1980 to 2010 Week 50>
EMBASE (updates since 2010-12-09)
<1>
Accession Number
2010651888
Authors
Faggian G. Forni A. Milano A.D. Chiominto B. Walpoth B.H. Scarabelli T.
Mazzucco A.
Institution
(Faggian, Forni, Milano, Chiominto, Mazzucco) Division of Cardiac Surgery,
University of Verona, Verona, Italy
(Walpoth) Division of Cardiac Surgery, University of Geneva, Geneva,
Switzerland
(Scarabelli) Department of Internal Medicine and Pharmacology, Wayne State
University School of Medicine, Detroit, MI, United States
Title
Antithymocyte globulin induction therapy in heart transplantation:
Prospective randomized study of high vs standard dosage.
Source
Transplantation Proceedings. 42 (9) (pp 3679-3687), 2010. Date of
Publication: November 2010.
Publisher
Elsevier USA (6277 Sea Harbor Drive, Orlando FL 32862 8239, United States)
Abstract
Background In cardiac transplantation, high-dose antithymocyte globulin
(ATG) induction therapy as short-term rejection prophylaxis has not been
used. Objective To evaluate the efficacy and safety of intraoperative use
of single high-dose ATG induction therapy after heart transplantation.
Patients and Methods Fourteen patients received single high-dose ATG
therapy plus shortened standard therapy (group1), and 16 patients received
ATG standard therapy (group2). Results No perioperative deaths were
reported. During follow-up, 3 deaths were recorded. Five- year patient
survival was 92.8% in groupl vs 85.7% in group2 (P = .34). The mean (SD)
number of acute rejection episodes per patient was 2.5 (2.2) in the
high-dose ATG group vs 2.7 (2.5) in the standard therapy group (P = .83),
with 5-year freedom from acute rejection of 45.5% in group 1 vs 35.6% in
group 2 (P = .85). Infections were observed in 6 patients in group1 and in
8 patients in group2 (P = .69). Malignant disease was diagnosed in 1
patient in the high-dose group and 3 patients in the standard therapy
group (P = .35). Chronic allograft vasculopathy was recognized in 4
patients (28%) in group1 and 8 (50%) in group2 (P = .05). Five-year
actuarial freedom from allograft vasculopathy was 69.2% in the high-dose
ATG group vs 50.0%% in the standard therapy group (P = .35). Conclusions
High-dose ATG for prevention of rejection episodes is safe and
efficacious, with a lower rate of early and late complications, in
particular, graft vasculopathy. 2010 by Elsevier Inc. All rights
reserved.
<2>
Accession Number
2010642199
Authors
Yin L. Wang Z.-N. Wang Y.-F. Wang W.-T. Ji G.-Y. Yang X.-W. Xu Z.-Y.
Institution
(Yin, Wang, Wang, Wang, Ji, Yang, Xu) Department of Cardiothoracic
Surgery, Changhai Hospital, Second Military Medical University of PLA,
Shanghai 200433, China
Title
Predictors of atrial fibrillation after coronary artery bypass graft: A
meta-analysis.
Source
Journal of Geriatric Cardiology. 6 (3) (pp 162-167), 2009. Date of
Publication: September 2009.
Publisher
Institute of Geriatric Cardiology (28 Fuxing Road, Beijing 100853, China)
Abstract
Objectives: Postoperative atrial fibrillation (AF) has been associated
with less favorable outcomes in patients undergoing coronary artery bypass
graft surgery (CABG) and may result in increased post-operative morbidity
and mortality. A systematic review and meta-analysis of published studies
was conducted to examine the risk factors of occurrence AF after CABG.
Methods: Using the Medline database, the Cochrane clinical trials database
and online clinical trial databases, we reviewed all randomized controlled
trials (RCTs) and observational studies examining the risk factors of
occurrence of AF after CABG. We searched for literature published April
2009 or earlier. Results: Our review identified 8 studies (observational
studies), involving 14548 patients, that examined the risk factors of
occurrence of AF after CABG. Although studies provide conflicting results,
the overall outcomes suggests that advanced age, previous hypertension,
numbers of bridge vessels may increase the occurrence of AF after CABG,
while no significant difference of diabetes, preoperative myocardial
infarction, and preoperative medication of beta-Blocker have been observed
between the AF patients and no-AF patiens. Conclusions: Patients with
advanced age, previous hypertension and more numbers of bridge vessels had
higher risk for the occurrence of AF after CABG, and perioperative
medication and care must be intensified to decrease the postoperative
occurrence of AF.
<3>
Accession Number
2010659524
Authors
Schulz S. Birkmeier K.A. Ndrepepa G. Moshage W. Dotzer F. Huber K.
Dirschinger J. Seyfarth M. Schomig A. Kastrati A. Mehilli J.
Institution
(Schulz, Birkmeier, Ndrepepa, Seyfarth, Schomig, Kastrati, Mehilli)
Deutsches Herzzentrum, Technische Universitat, Lazarettstrasse 36, Munich
80636, Germany
(Dirschinger, Schomig) Medizinische Klinik Rechts der Isar, Technische
Universitat, Munich, Germany
(Moshage) Klinikum Traunstein, Traunstein, Germany
(Dotzer) Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany
(Huber) Medizinische Klinik, Wilhelminenspital, Vienna, Austria
Title
One-year clinical outcomes with abciximab in acute myocardial infarction:
Results of the BRAVE-3 randomized trial.
Source
Clinical Research in Cardiology. 99 (12) (pp 795-802), 2010. Date of
Publication: December 2010.
Publisher
D. Steinkopff-Verlag (P.O. Box 100462, Darmstadt D-64204, Germany)
Abstract
Purpose: In the Bavarian Reperfusion Alternatives Evaluation (BRAVE)-3
study upstream administration of abciximab additional to 600 mg
clopidogrel loading did not reduce the infarct size in patients with acute
ST-segment elevation myocardial infarction (STEMI) undergoing primary
percutaneous coronary interventions. The aim of this study was to
investigate 1-year clinical outcomes in the BRAVE-3 study patients.
Methods: A total of 800 patients with acute STEMI within 24 h from symptom
onset, all treated with 600 mg of clopidogrel were randomized in a
double-blind fashion to receive either abciximab (n = 401) or placebo (n =
399) in the intensive care unit before being sent to the catheterization
laboratory. Results: The main outcome of interest of the present study,
the composite of death, recurrent myocardial infarction, stroke or
revascularization of the infarct-related artery (IRA) at 1 year, was 23.0%
(92 patients) in the abciximab versus 25.7% (102 patients) in the placebo
group [relative risk (RR) = 0.90, 95% confidence interval (CI) 0.67-1.20;
P = 0.46]. The combined incidence of death, recurrent myocardial
infarction or stroke was 9.3% in the abciximab group versus 6.0% in the
placebo group (RR = 1.55, 95% CI 0.93-2.58; P = 0.09). There was a
significant reduction of the IRA revascularization with abciximab compared
to placebo (16.3 vs. 22.3%, RR = 0.71, 95% CI 0.52-0.98; P = 0.04).
Conclusion: In patients with STEMI, all receiving 600 mg clopidogrel,
abciximab did not improve overall clinical outcomes at 1 year after
primary coronary stenting. 2010 Springer-Verlag.
<4>
Accession Number
2010660749
Authors
Ariff B.B. Glor F.P. Crowe L. Xu X.Y. Vennart W. Firmin D.N. Thom S.M.
Hughes A.D.
Institution
(Ariff, Thom, Hughes) International Centre for Circulatory Health,
National Heart and Lung Institute Division, Imperial College Healthcare
National Health Service Trust, London, United Kingdom
(Ariff) Department of Imaging, Imperial College National Health Service
Trust, Hammersmith Hospital, London W12 0HS, United Kingdom
(Glor, Xu) Department of Chemical Engineering, Faculty of Engineering,
Imperial College London, London, United Kingdom
(Crowe, Firmin) Cardiovascular Magnetic Resonance Unit, Royal Brompton
Hospital, Imperial College London, London, United Kingdom
(Vennart) Global Research and Development, Pfizer, Sandwich Laboratories,
Sandwich, Kent, United Kingdom
Title
Carotid artery hemodynamics: Observing patient-specific changes with
amlodipine and lisinopril by using MR imaging computation fluid dynamics.
Source
Radiology. 257 (3) (pp 662-669), 2010. Date of Publication: December
2010.
Publisher
Radiological Society of North America Inc. (820 Jorie Boulevard, Oak Brook
IL 60523-2251, United States)
Abstract
Purpose: To assess whether using magnetic resonance (MR) imaging combined
with computational fluid dynamics (CFD) could reveal changes in common
carotid artery (CCA) flow and wall shear stress (WSS) that might
contribute to differences in CCA remodeling between amlodipine, a calcium
channel blocker, and lisinopril, an angiotensin-converting enzyme
inhibitor, despite similar reductions in blood pressure (BP). Materials
and Methods: Institutional review board approval was obtained, and
participants gave informed consent. Nine subjects with hypertension were
recruited into a double-blind placebo-controlled randomized three-way
crossover study to compare the hemodynamic effects of 7 days of treatment
with placebo, amlodipine, or lisinopril. After each treatment period,
patients underwent CCA ultrasonography, BP measurement, and MR imaging
with CFD. Analyses were performed by using repeated-measures analysis of
variance, followed by the Tukey test or the Wilcoxon matched-pairs test.
Results: Amlodipine and lisinopril lowered BP similarly, but CCA flow rate
was significantly higher (P < .01) and distal vascular resistance was
lower (P =.016) after amlodipine treatment than after lisinopril
treatment. WSS on the inner wall of the CCA was significantly lower after
lisinopril treatment than after amlodipine treatment (P =.03). The change
in WSS in the CCA correlated with the change in vascular resistance (r =
-0.85, P < .001). Conclusion: Amlodipine causes increased blood flow and
increased time-averaged WSS in the CCA compared with lisinopril, despite
similar reductions in BP. Differences in the sub-acute hemodynamic effects
of amlodipine and lisinopril could contribute to the differences in CCA
remodeling seen in long-term studies. RSNA, 2010.
<5>
Accession Number
2010640044
Authors
Wang S. Cui J. Peng W. Lu M.
Institution
(Wang, Cui, Peng, Lu) Department of Cardiovascular Medicine, General
Hospital of Beijing Military Region of PLA, Nan Men Cang 5, Dongcheng
District, Beijing 100700, China
Title
Intracoronary autologous CD34+ stem cell therapy for intractable angina.
Source
Cardiology. 117 (2) (pp 140-147), 2010. Date of Publication: November
2010.
Publisher
S. Karger AG (Allschwilerstrasse 10, P.O. Box, Basel CH-4009, Switzerland)
Abstract
Background/Objectives: A large number of patients with coronary artery
disease experience angina that is not suitable for revascularization and
is refractory to conventional medical therapy. Laboratory and preclinical
studies have provided evidence for the safety and potential efficacy of
autologous CD34+ stem cell therapies as treatment for angina. Clinical
studies investigating intramyocardial transplantation of autologous CD34+
stem cells by catheter injection for patients with refractory angina show
that this is safe and feasible. It remains unclear whether intracoronary
infusion of CD34+ stem cells exerts beneficial effects in patients with
angina as well. We addressed this question with a controlled clinical
trial by enrolling 112 patients with refractory angina. Previous trials
have investigated the safety and beneficial effects of CD34+ cells
isolated from granulocyte colony-stimulating factor-mobilized peripheral
blood; in our trial, we isolated CD34+ cells directly from the patient's
bone marrow. Methods: One hundred and twelve patients with diffuse
triple-vessel disease and Canadian Cardiovascular Society class III or IV
angina were enrolled in a double-blind, randomized (1:1),
placebo-controlled study. Patients received optimal medical treatment but
were not candidates for mechanical revascularization (percutaneous
coronary intervention or coronary artery bypass grafting). Fifty-six
patients (27 women and 29 men aged 42-80 years) were enrolled in the
treatment group, and 56 patients (28 women and 28 men aged 43-80 years)
who received optimal medical treatment and intracoronary saline injections
were enrolled in the placebo control group. Bone marrow was collected from
all enrolled patients at a volume of 120-150 ml each in both groups.
Selections of CD34+ cells were performed by a CE-marked device approved by
the Security, Food and Drug Administration of China. Coronary angiography
had been performed before enrollment in this study. Results: No myocardial
infarction was observed during intracoronary infusion. The intracoronary
infusion of cells or saline did not result in cardiac enzyme elevation,
cardiac perforation or pericardial effusion. No arrhythmia, such as
ventricular tachycardia or ventricular fibrillation, was induced by
intracoronary infusion. No serious adverse events occurred in either
group. The reduction in the frequency of angina episodes per week 3 and 6
months after infusion was significantly higher in the treatment group
(-14.6 +/- 4.8 at 3 months and -15.6 +/- 4.0 at 6 months) than in the
control group (-4.5 +/- 0.3 and -3.0 +/- 1.2, respectively; p < 0.01).
Other efficacy parameters such as nitroglycerine usage, exercise time and
the Canadian Cardiovascular Society class also showed an improvement in
the treatment group compared to the control group. A significant
improvement in myocardial perfusion was noted in the treatment group
compared to the control group, as measured by single-photon emission
computed tomography. Conclusions: This randomized trial investigating
intracoronary infusion of autologous CD34+ cells in patients with
intractable angina shows the safety and feasibility of this therapy and
provides evidence for efficacy. Copyright 2010 S. Karger AG, Basel.
<6>
Accession Number
2010659232
Authors
Simpson Jr. R.J. Mendys P.
Institution
(Simpson Jr.) Division of Cardiology, University of North Carolina at
Chapel Hill, 6033 Burnett-Womack Building, 160 Dental Circle, Chapel Hill,
NC 27599-7075, United States
(Mendys) Pfizer Inc., University of North Carolina, Chapel Hill, NC,
United States
Title
The effects of adherence and persistence on clinical outcomes in patients
treated with statins: A systematic review.
Source
Journal of Clinical Lipidology. 4 (6) (pp 462-471), 2010. Date of
Publication: November-December 2010.
Publisher
Elsevier Ltd (Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom)
Abstract
Background: In clinical practice, medication adherence and persistence are
important for disease management and can significantly improve outcomes
and enhance the quality of patient care. Quantifying the relationship
between medication adherence/persistence and clinical outcomes with
statins can serve as an important therapeutic model and complement our
understanding of the critical relationship between medication use and
improved patient care. Methods and Results: A PubMed search was conducted
for literature published between 1999 and 2009 using the terms adherence,
compliance, HMG CoA, nonadherence, noncompliance, persistency,
persistence, and statin. Data on the direct relationship between adherence
or persistence to statin monotherapy and clinical outcomes were extracted.
A total of 19 articles met the inclusion criteria, including the clinical
impact of adherence (n = 15) and persistence (n = 4). High levels of
adherence were associated with reductions in adverse clinical outcomes,
including all-cause mortality and fatal and nonfatal cardiovascular
events; the most consistent benefits were witnessed at adherence levels
80% or greater. In primary prevention cohorts, clinical benefits were seen
after 1 year of therapy. Longer durations of treatment were associated
with incremental improvements in clinical outcomes as length of therapy
increased. Conclusions: High levels of adherence and longer durations of
persistence with statins are associated with progressively increasing
clinical benefits in primary and secondary prevention patient populations
at risk for cardiovascular events. Efforts to improve adherence and
persistence are warranted. 2010 National Lipid Association. All rights
reserved.
<7>
Accession Number
2010656615
Authors
Wagner R. Piler P. Bedanova H. Adamek P. Grodecka L. Freiberger T.
Institution
(Wagner, Adamek) Department of Cardiac Anaesthesia, Centre for
Cardiovascular and Transplant Surgery (CKTCH), St. Anne's University
Hospital, Brno, Czech Republic
(Piler) Department of Cardiosurgery, Centre for Cardiovascular and
Transplant Surgery (CKTCH), St. Anne's University Hospital, Brno, Czech
Republic
(Bedanova) Department of Cardiology, Centre for Cardiovascular and
Transplant Surgery (CKTCH), St. Anne's University Hospital, Brno, Czech
Republic
(Grodecka, Freiberger) Department of Molecular Genetics, Centre for
Cardiovascular and Transplant Surgery (CKTCH), St. Anne's University
Hospital, Brno, Czech Republic
Title
Myocardial injury is decreased by late remote ischaemic preconditioning
and aggravated by tramadol in patients undergoing cardiac surgery: A
randomised controlled trial.
Source
Interactive Cardiovascular and Thoracic Surgery. 11 (6) (pp 758-762),
2010. Date of Publication: December 2010.
Publisher
European Association for Cardio-Thoracis Surgery (3 Park Street, Windsor,
Berkshire SL4 1LU, United Kingdom)
Abstract
The purpose of this study was to test, whether the late phase of remote
ischaemic preconditioning (L-RIPC) improves myocardial protection in
coronary artery bypass grafting (CABG) with cold-crystalloid cardioplegia
and whether preoperative tramadol modifies myocardial
ischaemia-reperfusion injury using the same group of patients in a
single-blinded randomized controlled study. One hundred and one adult
patients were randomly assigned to either the L-RIPC, control or tramadol
group. L-RIPC consisted of three five-minute cycles of upper limb
ischaemia and three five-minute pauses using blood pressure cuff inflation
18 hours prior to the operation. Patients in the tramadol group received
200 mg tramadol retard at 19:00 hours, the day before the operation and at
06:00 hours. Serum troponin I levels were measured at eight, 16 and 24
hours after surgery. Myocardial samples for inducible and endothelial
nitric oxide synthases (iNOS, eNOS) estimation were drawn twice: before
and after cannulation for cardiopulmonary bypass from the auricle of the
right atrium. We found that L-RIPC can reduce injury beyond the myocardial
protection provided by cold-crystalloid cardioplegia, and tramadol
worsened myocardial injury after CABG. Expressions of iNOS were increased
in the control (significantly) and L-RIPC groups and dampened in the
tramadol group. 2010 Published by European Association for
Cardio-Thoracic Surgery. All rights reserved.
<8>
Accession Number
2010656616
Authors
Grauhan O. Navasardyan A. Hofmann M. Muller P. Hummel M. Hetzer R.
Institution
(Grauhan, Navasardyan, Hofmann, Muller, Hetzer) Department of
Cardiothoracic and Vascular Surgery, German Heart Institute Berlin,
Berlin, Germany
(Hummel) Department of Internal Medicine and Cardiology, Paulinen
Hospital, Berlin, Germany
Title
Cyanoacrylate-sealed Donati suture for wound closure after cardiac surgery
in obese patients.
Source
Interactive Cardiovascular and Thoracic Surgery. 11 (6) (pp 763-767),
2010. Date of Publication: December 2010.
Publisher
European Association for Cardio-Thoracis Surgery (3 Park Street, Windsor,
Berkshire SL4 1LU, United Kingdom)
Abstract
The majority of wound infections after median sternotomy in obese patients
are triggered by the breakdown of skin suture and subsequent seepage of
skin flora into the deeper tissue layers. In a prospective study, 90
patients (body mass index >=30) who had cardiac surgery via median
sternotomy were enrolled. In 45 patients, skin closure was performed
according to the Donati technique (vertical interrupted mattress suture)
and sealed with octylcyanoacrylate (group A). In 45 patients,
intracutaneous running technique without sealed was performed (group B).
The endpoint was wound infection within 90 days. Degree of obesity and
other risk factors for wound infection were equally distributed between
groups A and B (all P>0.05). In group A only two superficial infections
occurred, whereas in group B there were nine wound infections including
two deep infections (P=0.026). In 10 of 11 infections (both groups)
coagulase-negative staphylococci were isolated. In eight of 11 wound
infections the caudal third of the incision was affected. Intertrigo in
inframammary skin folds was found in 20.0% (18/90) of all patients but in
63.6% (seven of 11) of cases with infection. We conclude, that
cyanoacrylate-sealed Donati suture is superior to intracutaneous suture
technique since it offers tension-resistant closure with immediate
microbial barrier properties. 2010 Published by European Association for
Cardio-Thoracic Surgery. All rights reserved.
<9>
Accession Number
2010656619
Authors
Memetoglu M.E. Kurtcan S. Kalkan A. Ozel D.
Institution
(Memetoglu, Kurtcan, Kalkan, Ozel) Department of Cardiovascular Surgery,
Gumushane State Hospital, 29000 Gumushane, Turkey
Title
Combination technique of tumescent anesthesia during endovenous laser
therapy of saphenous vein insufficiency.
Source
Interactive Cardiovascular and Thoracic Surgery. 11 (6) (pp 774-777),
2010. Date of Publication: December 2010.
Publisher
European Association for Cardio-Thoracis Surgery (3 Park Street, Windsor,
Berkshire SL4 1LU, United Kingdom)
Abstract
Objective: This study aimed at evaluating the efficiency of applying
tumescent anesthesia before an ablation procedure and continuously during
endovenous laser treatment (EVLT) (combined tumescent technique) of
saphenous vein insufficiency to reduce the patients pain and discomfort.
Methods: Twenty-five patients with 31 duplex-confirmed great saphenous
vein insufficiency underwent endovenous laser (940 nm) varicose vein
treatment between December 2009 and April 2010. The patients were
randomized in two groups. In group A (15 patients) tumescent anesthesia
was used before the ablation procedure and in group B (10 patients)
tumescent anesthesia was used before and continuously during the
procedure. Patients were scheduled for a three-day examination after EVLT
to assess the level of pain experienced. Results: According to the
statistic analysis we observed that the mean level of pain score for the
patients given classical tumescent anesthesia showed a higher level
(P=0.003) compared with the patients given tumescent anesthesia in the
combined procedure. Conclusion: Combination technique of administering
tumescent anesthesia before ablation and continuously during the EVLT
procedure may be an alternative way to reduce the patient's peroperative
pain and discomfort. 2010 Published by European Association for
Cardio-Thoracic Surgery. All rights reserved.
<10>
Accession Number
2010645092
Authors
Imazio M. Trinchero R. Brucato A. Rovere M.E. Gandino A. Cemin R. Ferrua
S. Maestroni S. Zingarelli E. Barosi A. Simon C. Sansone F. Patrini D.
Vitali E. Ferrazzi P. Spodick D.H. Adler Y.
Institution
(Imazio, Trinchero) Department of Cardiology, Maria Vittoria Hospital, Via
Cibrario 72, 10141 Torino, Italy
(Brucato, Maestroni, Simon, Ferrazzi) Ospedali Riuniti, Bergamo, Italy
(Rovere, Zingarelli, Sansone) Cardiac Surgery, Ospedale Mauriziano,
Torino, Italy
(Gandino, Barosi, Patrini, Vitali) Ospedale Niguarda, Milano, Italy
(Cemin) Department of Cardiology, San Maurizio Regional Hospital, Bolzano,
Italy
(Ferrua) Ospedale Degli Infermi, Rivoli, Italy
(Spodick) Department of Medicine, St Vincent Hospital, University of
Massachusetts, Worcester, MA, United States
(Adler) Sackler Faculty of Medicine, Tel-Aviv, Misgav Ladach Hospital,
Jerusalem, Kupat Holim Meuhedet, Israel
(Patrini, Vitali) Humanitas Gavazzeni, Bergamo, Italy
Title
COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS):
A multicentre, randomized, double-blind, placebo-controlled trial.
Source
European Heart Journal. 31 (22) (pp 2749-2754), 2010. Date of
Publication: November 2010.
Publisher
Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United
Kingdom)
Abstract
AimsNo drug has been proven efficacious to prevent the post-pericardiotomy
syndrome (PPS), but colchicine seems safe and effective for the treatment
and prevention of pericarditis. The aim of the COlchicine for the
Prevention of the Post-pericardiotomy Syndrome (COPPS) trial is to test
the efficacy and safety of colchicine for the primary prevention of the
PPS.Methods and resultsThe COPPS study is a multicentre, double-blind,
randomized trial. On the third post-operative day, 360 patients (mean age
65.7 +/- 12.3 years, 66 males), 180 in each treatment arm, were randomized
to receive placebo or colchicine (1.0 mg twice daily for the first day
followed by a maintenance dose of 0.5 mg twice daily for 1 month in
patients >=70 kg, and halved doses for patients <70 kg or intolerant to
the highest dose). The primary efficacy endpoint was the incidence of PPS
at 12 months. Secondary endpoint was the combined rate of disease-related
hospitalization, cardiac tamponade, constrictive pericarditis, and
relapses. Baseline characteristics were well balanced between the study
groups. Colchicine significantly reduced the incidence of the PPS at 12
months compared with placebo (respectively, 8.9 vs. 21.1; P = 0.002;
number needed to treat = 8). Colchicine also reduced the secondary
endpoint (respectively, 0.6 vs. 5.0; P = 0.024). The rate of side effects
(mainly related to gastrointestinal intolerance) was similar in the
colchicine and placebo groups (respectively, 8.9 vs. 5.0; P =
0.212).ConclusionColchicine is safe and efficacious in the prevention of
the PPS and its related complications and may halve the risk of developing
the syndrome following cardiac surgery. ClinicalTrials.gov number,
NCT00128427. 2010 The Author.
No comments:
Post a Comment